ImmunoCellular Therapeutics, Ltd Announces First Patient Receives Vaccine In Phase I Trial Of Cancer Vaccine ICT-121 In Recurrent Glioblastoma

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine. ICT-121 is a dendritic cell vaccine targeting CD-133, an important cancer stem cell marker that is commonly expressed on a broad range of solid tumors. The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA. ImmunoCellular is supporting the trial by providing the ICT-121 vaccine.

Help employers find you! Check out all the jobs and post your resume.